To test the involvement of the β-ARs in the maintenance of cancer-related pain in osteosarcoma-bearing mice, we treated the mice (daily) with the β1-AR antagonist atenolol, the β1/2-AR antagonist propranolol and the β3-AR antagonist SR59230A. Here, AR is linked to osteosarcoma.